Axis Securities Recommends Buy on Three Indian Diagnostics Stocks Citing Growth Potential
Axis Securities has assigned 'Buy' ratings to Dr Lal PathLabs, Vijaya Diagnostic Centre, and Nephrocare Health Services, projecting potential upside of 20-21%. The brokerage highlights India's diagnostics sector as poised for multi-year growth driven by structural demand, scalable models, and strong cash flows. Key strengths include pan-India networks, high EBITDA margins, and disciplined expansion. The sector is expected to grow at a 10-12% CAGR to reach Rs 1.27-1.37 lakh crore by FY28, reflecting increasing consumer preference for organized diagnostics and specialized healthcare services.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 34/100.
Outlets measured: mint, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 12 Oct, 07:35 am. Other outlets followed.